CCL5 and Parkinson disease: Concomitantly, PD patients display a systemic dysregulation of inflammatory markers, including elevated IL-6, TNF, IL-1β, CRP, and CCL5, alongside altered levels of anti-inflammatory mediators, such as IL-10 and IL-2, suggesting a shift toward a pro-inflammatory immune phenotype.